itacitinib + erlotinib

**Itacitinib + erlotinib** is an investigational combination therapy consisting of **itacitinib**, a selective Janus kinase 1 (JAK1) inhibitor, and **erlotinib**, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Erlotinib inhibits EGFR-mediated signaling by blocking phosphorylation of tyrosine kinase, thereby preventing tumor cell proliferation and survival. Itacitinib targets JAK1 and interferes with cytokine-driven signaling involved in cancer cell growth and immune regulation. The combination was explored for its potential to overcome EGFR TKI resistance and enhance inhibition of downstream pathways in non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. A phase 2 trial in this indication was initiated but later withdrawn[5][6][2][4].